Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
4
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
roche
4
×
san francisco blog main
4
×
deals
fda
genentech
san francisco top stories
avapritinib
blueprint medicines
cancer
clinical trials
eli lilly
investing
medullary thyroid cancer
non-small cell lung cancer
novartis
pralsetinib
selpercatinib
thyroid cancer
biofourmis
biovotion
cancer drugs
cancer immunotherapy
capmatinib
center for medicare and medicaid services
chugai pharmaceutical
companion diagnostic
cstone pharmaceuticals
daniel o'day
edbi
europe blog main
europe top stories
european medicines agency
fisogatinib
What
approval
blueprint
cancer
drug
fda
medicines
ret
roche
acquire
address
agreed
analytics
approves
big
billion
biofourmis
broad
candidate
carries
certain
confidence
currently
data
designed
devices
didn’t
digital
employs
foundation
gain
genentech
genetic
globally
hauls
help
latest
marketing
medicine
million
momentum
Language
unset
Current search:
boston
×
roche
×
" san francisco blog main "
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
